Singular Genomics : Investor Presentation August 2023

Company Presentation

August 2023

F O R W A R D - LOOKING STATEMENTS

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully manufacture, commercialize and support the G4 and our F3 flow cells in accordance with our timelines, objectives and specifications; (ii) our ability to close sales in our sales funnel and effectively expand our international commercial presence and customer base; (iii) our ability to release Max Read kits to our broader customer base on our timeline; (iv) the ability of our product offerings to successfully compete with existing and new products offered by our competitors; (v) our ability to achieve customer and scientific acceptance of the G4; and (vi) quotes of management. Any such forward-looking statements are based on our management's current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management's current expectations or those implied by our forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have very little history manufacturing and commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our products; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; (vi) we expect to be highly dependent upon revenue generated from the sale of the G4 and planned PX, and any delay or failure by us to successfully manufacture and commercialize the G4 and planned PX could have a substantial adverse effect on our business and results of operations; and (vii) recent macroeconomic challenges such as inflation and rising interest rates may materially and adversely impact our business, operations and product manufacturing and commercialization objectives. These and other risk factors that may affect our future results of operations are identified and described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time, including our Quarterly Report on Form 10-Q for the period ended June 30, 2023, filed with the SEC on August 9, 2023. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size, growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

The performance information in this presentation and the associated discussion regarding our G4 instrument and consumable kits are reported at target specifications, and the performance of third-party instruments are reported based on specifications publicly available on such third party's website.

This presentation contains references to our trade names, trademarks and service marks and to those belonging to third parties. We do not intend our use or display of a third party's trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, such third party.

2

COMPANY MISSION

Accelerating Genomics for the

Advancement of Science and Medicine

3

COMPANY OVERVIEW

Headquartered in San Diego, CA

OMIC	G4	270+	200+
NASDAQ ticker	NGS instrument	Employees	Issued and pending
IPO May 2021	on-market	0	patents

As of August 1, 2023	4

PRESENTATION CONTENTS

• Market Opportunity Solutions for large and growing markets

2 G4 Platform

Product overview, on-market feedback, data and ecosystem

• Business Execution Operations, commercial and development

5